Solid Neoplasm With Neurotrophic Receptor Tyrosine Kinase Gene Fusion — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for solid neoplasm with neurotrophic receptor tyrosine kinase gene fusion. 28 active patents protecting 1 drugs from 1+ originators. First major cliff: 2028. Daily refresh.

1
Approved drugs
28
Active US patents
51/100
Avg vulnerability
$300M
Annual revenue covered

Originators in Solid Neoplasm With Neurotrophic Receptor Tyrosine Kinase Gene Fusion

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Roche 28 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating solid neoplasm with neurotrophic receptor tyrosine kinase gene fusion. Each bar = one year. Y-axis scaled to peak year (10 patents).

10
28
2
32
4
33
4
35
4
37
4
38

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Rozlytrek
entrectinib
 Roche 28 51 $300M 2028-07-08

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9616059 Rozlytrek method of use 75 2028-07-08
9616059 Rozlytrek method of use 75 2028-07-08
8673893 Rozlytrek method of use 75 2028-07-08
9255087 Rozlytrek method of use 75 2028-07-08
8673893 Rozlytrek method of use 75 2028-07-08
9255087 Rozlytrek method of use 75 2028-07-08
9649306 Rozlytrek method of use 62 2033-05-22
9649306 Rozlytrek method of use 62 2033-05-22
10231965 Rozlytrek method of use 62 2035-02-17
10231965 Rozlytrek method of use 62 2035-02-17

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9085565 Rozlytrek composition of matter 4 2033-05-22
9085565 Rozlytrek composition of matter 4 2033-05-22
8299057 Rozlytrek composition of matter 10 2032-03-10
8299057 Rozlytrek composition of matter 10 2032-03-10
9029356 Rozlytrek composition of matter 17 2028-07-08
9029356 Rozlytrek composition of matter 17 2028-07-08
10398693 Rozlytrek formulation 42 2038-07-18
10398693 Rozlytrek formulation 42 2038-07-18
11253515 Rozlytrek formulation 50 2038-07-18
11253515 Rozlytrek formulation 50 2038-07-18

Related